New drug shows promise for lupus in asian patients
NCT ID NCT04931563
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a drug called anifrolumab in 277 Asian adults with active lupus. The goal was to see if it could better control the disease compared to a placebo, when added to standard treatments. Participants received the drug or placebo through an IV, and researchers measured how many had less disease activity after one year.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Baoding, 071000, China
-
Research Site
Baotou, 014010, China
-
Research Site
Beijing, 100029, China
-
Research Site
Beijing, 100034, China
-
Research Site
Beijing, 100144, China
-
Research Site
Beijing, 100191, China
-
Research Site
Beijing, 100730, China
-
Research Site
Bengbu, 233004, China
-
Research Site
Binzhou, 256603, China
-
Research Site
Changchun, China
-
Research Site
Changsha, 410008, China
-
Research Site
Chuangchun, 130012, China
-
Research Site
Guangzhou, 510080, China
-
Research Site
Guangzhou, 510260, China
-
Research Site
Guilin, 541001, China
-
Research Site
Hangzhou, 310006, China
-
Research Site
Hengyang, 421001, China
-
Research Site
Jieyang, 522000, China
-
Research Site
Jinan, 250012, China
-
Research Site
Jining, 272011, China
-
Research Site
Kunming, 650032, China
-
Research Site
Lanzhou, 730000, China
-
Research Site
Linyi, 276003, China
-
Research Site
Luoyang, 471003, China
-
Research Site
Nanchang, 330006, China
-
Research Site
Nanchong, 637000, China
-
Research Site
Nanjing, 210008, China
-
Research Site
Nanyang, 473005, China
-
Research Site
Shanghai, 200025, China
-
Research Site
Shengyang, 110004, China
-
Research Site
Shenyang, 110001, China
-
Research Site
Shenzhen, 518020, China
-
Research Site
Shijiazhuang, 050001, China
-
Research Site
Suzhou, 215006, China
-
Research Site
Tianjin, 300050, China
-
Research Site
Ürümqi, 831118, China
-
Research Site
Wenzhou, 325000, China
-
Research Site
Wuhan, 430022, China
-
Research Site
Wuhan, 430030, China
-
Research Site
Wuxi, 214002, China
-
Research Site
Xiamen, 361003, China
-
Research Site
Xinxiang, 453002, China
-
Research Site
Yinchuan, 750004, China
-
Research Site
Zaozhuang, 277102, China
-
Research Site
Zhengzhou, 450052, China
-
Research Site
Hong Kong, 00000, Hong Kong
-
Research Site
Hong Kong, Hong Kong
-
Research Site
Davao City, PH-8000, Philippines
-
Research Site
Iloilo City, 5000, Philippines
-
Research Site
Lipa City, 4217, Philippines
-
Research Site
Manila, 1000, Philippines
-
Research Site
Quezon City, 1112, Philippines
-
Research Site
Gwangju, 501-757, South Korea
-
Research Site
Seoul, 04763, South Korea
-
Research Site
Seoul, 6591, South Korea
-
Research Site
Suwon, 16499, South Korea
-
Research Site
Kaohsiung City, 81362, Taiwan
-
Research Site
New Taipei City, 220, Taiwan
-
Research Site
New Taipei City, 23561, Taiwan
-
Research Site
Taichung, 40447, Taiwan
-
Research Site
Taichung, 40705, Taiwan
-
Research Site
Taipei, 11220, Taiwan
-
Research Site
Taipei, 114, Taiwan
-
Research Site
Taoyuan, 333, Taiwan
-
Research Site
Bangkok, 10400, Thailand
More trials for these conditions
Other studies related to the condition(s) this trial covers.